Abstract 11008: Growth Differentiation Factor-15 is a Useful Biomarker to Distinguish between Hypertrophic Cardiomyopathy and Hypertensive Hearts
Introduction: To distinguish hypertrophic cardiomyopathy (HCM) and hypertensive left ventricular hypertrophy (H-LVH) based on a morphological examination is often challenging. Growth differentiation factor 15 (GDF-15) is a novel diagnostic and prognostic biomarker for several cardiovascular diseases.
Hypothesis: In patients with LVH, GDF-15 could be a useful biomarker to distinguish between HCM and H-LVH.
Methods and results: We measured serum GDF-15 levels in 62 patients with H-LVH, 31 with HCM, and 29 control individuals. Circulating GDF-15 and B-type natriuretic peptide (BNP) levels were significantly higher in LVH group than that in control group. In LVH group, serum GDF-15 levels were significantly higher in patients with H-LVH than with HCM [median 3208.7, interquartile range (2443.2-1968.0) vs. 2701.6 (2220.5-3601.1) pg/ml, p=0.014] (Figure 1A). On the other hand, plasma BNP levels were significantly lower in patients with H-LVH than with HCM [67.9 (27.4-159.1) vs. 98.6 (32.8-244.0) pg/ml, p=0.014] (Figure 1B). Multivariate logistic regression analysis revealed that GDF-15 is an independent predictor of H-LVH among patients with LVH (odds ratio; 1.40, confidence interval; 1.03-1.90, p=0.031). Serum GDF-15 and plasma BNP levels positively correlated in patients with H-LVH (r=0.55, p<0.001) but not with HCM (r=0.24, p=0.19). Furthermore, in H-LVH group, serum GDF-15 levels were significantly higher in patients with heart failure (HF) than those without [5544.2 (3982.1-6925.5) vs. 2708.4 (2163.3-3205.6) pg/ml, p=0.003]. Whereas, serum GDF-15 levels were not significantly different between HCM patients with or without HF [3648.8 (2862.5-4515.0) vs. 2355.6 (2095.8-2765.6) pg/ml, p=0.089].
Conclusions: GDF-15 could be a useful biomarker for discriminating HCM from H-LVH. Understanding serum GDF-15 values might have clinical utility for patients with LVH because the therapeutic strategies for treating HCM and H-LVH differ.
- © 2012 by American Heart Association, Inc.